Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR with or without pegvisomant in previously controlled acromegaly
NL-OMON26386Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of pasireotide LAR and pegvisomant in acromegaly (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary efficacy endpoint. Started Aug 2015; status: active, not recruiting.
02
Drugs
pasireotide LARpegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on NL-OMON26386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26386.